BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $30
Inmune Bio's Promising Future: Buy Rating Backed by Key Data Releases and Innovative Approaches
Raymond James Maintains INmune Bio(INMB.US) With Buy Rating, Raises Target Price to $23
Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $23
A. G. P. Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $20
Alliance Global Partners Reaffirms Their Buy Rating on Inmune Bio (INMB)
Scotiabank Remains a Buy on Inmune Bio (INMB)
Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $23
Inmune Bio (INMB) Receives a Buy From Scotiabank
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Raises Target Price to $30
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
A. G. P. Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $20
INmune Bio Is Maintained at Sector Outperform by Scotiabank
INmune Bio Analyst Ratings
Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Raises Target Price to $23
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
Rodman & Renshaw Initiates INmune Bio(INMB.US) With Buy Rating, Announces Target Price $23
INmune Bio Initiated With a Buy at Rodman & Renshaw
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22